Nambirajan Aruna, Suri Vaishali, Kataria Vijay, Sharma Mehar C, Goyal Vinay
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Neurol India. 2017 Sep-Oct;65(5):1061-1064. doi: 10.4103/neuroindia.NI_535_16.
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the central nervous system caused by the reactivation of John Cunningham virus (JCV) in immunocompromised patients, most commonly in human immunodeficiency virus (HIV) infection, and less commonly in those receiving various immunosuppressive regimens. Prognosis of untreated PML is grave and the mainstay of treatment is the reversal of immunosuppression, usually by institution of antiretroviral drugs in HIV patients and cessation of immunosuppressive therapies in others. PML is increasingly being reported in those with minimal or occult immunosuppression. A small fraction of these patients meet the criteria for idiopathic CD4+ T-lymphocytopenia (ICL) after exclusion of all secondary causes of lymphocytopenia, including HIV. A 44-year-old previously healthy male presented with clinical and radiological features suggestive of PML. Cerebrospinal fluid samples were repeatedly negative for JCV. Immunohistochemistry on brain biopsy eventually confirmed PML. Despite extensive work-up, the only abnormality detected was an unexplained and persistently low absolute CD4+ T-lymphocyte count. Based on the limited available literature on the treatment of non-HIV PML, he was treated with a combination of mirtazapine and mefloquine with clinical improvement. Non-HIV PML remains relatively uncommon, and PML as a presenting feature of ICL is rare. It is important to document and follow these patients to be able to assess the relative risks associated with various causes and formulate effective therapeutic strategies.
进行性多灶性白质脑病(PML)是一种中枢神经系统的机会性病毒感染,由免疫功能低下患者体内的约翰·坎宁安病毒(JCV)重新激活引起,最常见于人类免疫缺陷病毒(HIV)感染患者,较少见于接受各种免疫抑制方案的患者。未经治疗的PML预后严重,主要治疗方法是逆转免疫抑制,通常在HIV患者中使用抗逆转录病毒药物,在其他患者中停止免疫抑制治疗。越来越多的报道称,PML在免疫抑制轻微或隐匿的患者中出现。在排除包括HIV在内的所有淋巴细胞减少的继发原因后,这些患者中有一小部分符合特发性CD4+T淋巴细胞减少症(ICL)的标准。一名44岁以前健康的男性出现了提示PML的临床和影像学特征。脑脊液样本多次检测JCV均为阴性。脑活检的免疫组织化学最终确诊为PML。尽管进行了广泛的检查,但唯一检测到的异常是无法解释且持续偏低的绝对CD4+T淋巴细胞计数。基于关于非HIV相关PML治疗的有限文献,他接受了米氮平和甲氟喹联合治疗,临床症状有所改善。非HIV相关PML仍然相对少见,而PML作为ICL的首发特征则更为罕见。记录并跟踪这些患者对于评估与各种病因相关的相对风险以及制定有效的治疗策略非常重要。